|
Multifunctional Drug and Immune Modulator Delivery Nanoparticles for the Treatment of Cancer Patients with Comorbid Atherosclerosis
Application
A multifunctional immuno-therapy nanoparticle (PD1Y-HANP/Avasimbe) that has ability of targeting and inhibiting immune checkpoint PDL-1 while producing therapeutic effects on tumors and atherosclerosis.
Key Benefits
Multifunctional immunotherapy for cancer patients with atherosclerosis.
Shown to inhibit tumor growth and prevention...
Published: 1/10/2024
Contributor(s): Lily Yang, Lei Zhu
|
|
Biodegradable Nanoparticle Encapsulating Anti-Cancer Drug for the Treatment of Therapy-Resistant Cancers
Application
A targeted polymeric nanoparticle drug that inhibits NADPH Oxidase (NOX1/4)-Reactive oxygen species (ROS) signal for the treatment of chemotherapy drug and radiotherapy resistant cancers.
Key Benefits
Inhibits tumor growth.
Dual chemo-and radiotherapy enhancer.
Excellent biocompatibility and stability.
CD44 targeted drug delivery...
Published: 3/19/2024
Contributor(s): Lily Yang, Lei Zhu
|
|
Targeted Theranostic NanoToxin for Treating Metastatic and Drug-resistant Tumors
Application
Magnetic theranostic nano-toxin for imaging and drug delivery applications in cancer therapy.
Key Benefits
Induces tumor cell death via a different biological mechanism, compared to current chemotherapeutics, to overcome drug resistance mechanisms in tumor cells.
Delivers high levels of therapeutic agents into metastatic tumors, while...
Published: 11/27/2023
Contributor(s): Lily Yang, Xiangxue Guo, Hui Mao, Wei Chen
|
|
Targeted Anti-Cancer Nanoparticle Therapy
Application
A drug-carrying nanoparticle that selectively targets cancer cells.
Key Benefits
Incorporates an already proven anti-cancer therapeutic.
Increases deliverability.
Targets cancer cells.
Market Summary
Tris DBA palladium has been shown to have anti-cancer activity against melanoma and pancreatic cancer. However, Tris DBA has not...
Published: 4/8/2024
Contributor(s): Jack Arbiser, Lily Yang
|
|
Theranostic Nanoparticles for Activation of Tumor-Specific Immune Responses
Application
Tumor-targeted nanoparticles for the delivery of anti-PD-L1 peptides for treatment of cancers.
Key Benefits
Nanoparticles loaded with a variety of drugs and/or peptides for prolonged therapeutic delivery to tumor sites.
Targeted delivery to tumor sites can reduce level of dosing and side effects.
Market Summary
PD-L1 is expressed...
Published: 4/8/2024
Contributor(s): Lily Yang, Erica Bozeman
|
|
Anti-biofouling Polymer for Nanoparticle Coating
Application
A functionally amenable copolymer of polyethylene glycol (PEG) and allyl glycidyl ether (AGE) that improves the specificity and targeting of nanoparticles compared to PEG coating.
Key Benefits
Amphiphilic properties significantly reduce non-specific adsorbtion of proteins compared to PEG.
Improves targeting and cell-specific uptake...
Published: 11/27/2023
Contributor(s): Hui Mao, Yuancheng Li, Lily Yang
|
|
A Ligand-Protease Fusion Peptide for Enhanced Tumor Targeting and Drug Delivery
Application
A ligand-protease fusion peptide that cuts through the tumor stromal barrier and provides enhanced tumor targeting and delivery efficiency for therapeutic agents.
Key Benefits
The protease activity of the fusion peptide enables breaking of the stromal matrix and allows migration into stroma-rich tumor tissues.
Can be attached to nanoparticles...
Published: 3/1/2024
Contributor(s): Lily Yang, Xiangxue Guo
|
|
Nanoparticle Carrying siRNA DNA Cassette to Target Survival Genes in Cancer Treatment
Application
Tumor receptor-targeted nanoparticle containing a siRNA DNA cassette for the knockdown of survival genes and treating cancer.
Key Benefits
Nanoparticles are targeted directly to tumors for treatment and/or diagnostic imaging.
siRNA encoded by a DNA cassette has increased stability and more effective gene depletion.
siRNA knockdown...
Published: 11/6/2023
Contributor(s): Lily Yang
|